Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multicentre - Australia 1. Prince Charles Hospital, 2. Lady Cilento, 3. SCGH

    Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (VX17-659-102) , protocol number NCT03447249 VX17-659-102

    This randomized, placebo-controlled study will be taking place at multiple care centers across the U.S. It will evaluate the effectiveness, safety, and effect on the body of the drug VX-659 in combination with tezacaftor and ivacaftor. It is for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation

    • Age:

      12 years and older

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Queensland University of Technology Contact: Jeremy Russell - phone:07 3069 7552 email: j21.russell@hdr.qut.edu.au. To get started, go to: https://rebrand.ly/HYPRS-CF

    Helping Young People Reduce the Stress of Cystic Fibrosis Study , protocol number The HYPRS-CF Study 1800000294 (UHREC Reference number)

    Researchers at QUT are conducting a national, online research study with young people with Cystic Fibrosis (CF). The goal of this study is to learn how young people think and feel about the stress of CF and whether a social robot could possibly help them cope with this stress.

    • Age:

      10-18 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation (VX17-659-103) , protocol number NCT03460990 VX17-659-103

    This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the effectiveness and safety of the drug VX-659 in combination with ivacaftor and tezacaftor. It is for people with CF ages 12 and older who have two copies of the F508del CFTR mutation.

    • Age:

      12 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      7

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: USA

    Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number DPM-CF-303 NCT02134353

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug mannitol and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      6

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia - QLD

    A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects , protocol number FDL169-2015-04 NCT03093714

    A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation

    • Age:

      18 Years to 85 Years

    • Mutation(s):

      Homozygous for the F508del-CFTR mutation.

    • FEV1% Predicted:

      (FEV1) >40% of predicted normal for age, sex and height.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Australian Sites: Adelaide, Brisbane, Melbourne, Newcastle, Sydney Westmead, Sydney Randwick, Perth

    Saline Hypertonic in pre-schoolers + CT (SHIP-CT) , protocol number SHIP002 (SHIPCT) NCT02950883 & ACTRN12615001067561p

    The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks reduces structural lung disease as assessed by computed tomography (CT) in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 6) with cystic fibrosis.

    • Age:

      3-5 years

    • Mutation(s):

      A documented genotype with two disease-causing mutations in the CFTR gene

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      6

    • Length of Participation:

      54 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: LOCATION: Perth Linear Clinical Research, Contact: Jennifer Seabourne CONTACT: Greenteam@linear.org.au. Brisbane-Q-pharm CONTACT: Sharon Rankine Phone: 0439 664 900,; Email: s.rankine@qpharm.com.au

    A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants , protocol number FDL176-2016-01 NCT03173573

    This is a 5-part study. Part 1 is a double blind, placebo-controlled, dose escalation, first-in-human study to assess the safety, tolerability and PK profiles following single oral administration of FDL176 to healthy male participants. Part 2 is a single dose, open-label study in healthy male participants to determine the effect of food on the PK profile of FDL176. Part 3 is a single dose, double blind, placebo-controlled study in healthy female participants to assess the PK, safety and tolerability profiles of FDL176. Part 4 is a randomised, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and PK profiles following multiple oral administrations of FDL176 to healthy male and female participants. Part 5 is a single dose, open-label study in male and female participants with CF to determine the PK profile of FDL176.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA & Australia

    Phase 3 study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides. , protocol number PTC124-GD-021-CF NCT02139306

    This study is taking place at multiple care centers across the U.S. It looked at the effectiveness and safety of the oral drug ataluren in people with CF who have a nonsense mutation of cystic fibrosis. This study used a placebo control.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      56 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Cohort 3 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis QBW276 - Cohort 3

    This randomized, placebo-controlledstudy is taking place at multiple care centers across the US. This study will look at the safety, effectiveness and tolerability of the inhaled drug QBW276.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      15

    • Length of Participation:

      3 months

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    PREDICT: NTM observational study (NTM-OB-17) , protocol number NCT02073409 NTM-OB-17

    This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

    • Age:

      10 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      20

    • Length of Participation:

      5 Years

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 150)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|